P151 Characterization of platelet activation profile in Inflammatory Bowel Disease

J L Rueda Garcia,E Martín Arranz,L Ramírez García,C Suárez Ferrer,M Sánchez Azofra,J Poza Cordón,C Amiama Roig,J Noci Belda,L Perosanz,C Cubillo García,C García-Rojas,K Silva,E Monzón Manzano,E G Arias-Salgado,P Acuña,N Butta,M D Martín Arranz

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0281

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Platelet-related markers associated with a procoagulant state have been described for Immune-mediated Inflammatory Diseases (IMIDs), but a broader profiling of these abnormalities in Inflammatory Bowel Disease (IBD) is lacking. Methods Cross-sectional study to describe and compare platelet biomarkers of IBD outpatients, both Crohn’s Disease (CD) and Ulcerative Colitis (UC), vs healthy controls (HC). Patients over 18 years old with a diagnosis of CD or UC according to the European Crohn’s and Colitis Organization (ECCO) criteria were included. Fecal calproctectin (Fcal) >=150ug/g was used as a cutoff level for active disease. Exclusion criteria for IBD patients are listed under Table 1. Fibrinogen (FBG) receptor on platelet’s surface was determined with anti-CD41 and anti-CD61 monoclonal antibodies (mAbs); and von Willebrand factor receptor with anti-CD42a and anti-CD42b mAbs. Platelet activation markers [TRAP and ADP-induced activation of fibrinogen (FBG) receptor, and P-selectin (Psel) and CD63 exposure] were determined, respectively, through binding of PAC1, anti-P-selectin and anti-CD63 (mAbs). All variables were determined by flow cytometry. Results 55 patients (27 CD, 28 UC) and 75 HC have been included. 43 IBD patients had active disease (21 CD, 22 UC). Complete baseline characteristics of the IBD population are described in Table 1. Basal Psel (% of positive cells) was increased in CD vs UC (median [IQR]: 5.64 [4,4-10,4] vs 2,9 [1,8-6,8], p=0,02) and vs HC (3,5 [1,4-6,8], p=0,008). ADP-induced Psel was increased in CD vs HC (mean, SD: 49.92, SD 12.75 vs 41.943, SD13.15, p=0,007). Basal CD63 (% of positive cells) was significantly higher in active IBD vs HC (W = 1143, p = 0.02) and inactive IBD vs HC (W = 528, p= 0.006). CD42a (% of positive cells) was decreased in IBD vs HC (W = 1128.00, p=0.007) and CD vs HC (W = 777.00, p =0.04). CD42b (% of positive cells) was also decreased in IBD vs HC (mean, SD: 106.9 SD, 17.32 vs 115.7, SD 28.42, p=0,01) and CD vs HC (104.06 SD 14.49, p=0,03). No differences in basal or TRAP/ADP induced PAC binding, and in CD41 or CD61 expression were observed among groups. Multiple linear regression showed association of Fcal with basal Psel in IBD patients (p=0,02); and Spearman’s correlation showed negative moderate correlation between Fcal and basal Psel (r=0,3; p=0,003) Conclusion Features of platelets in IBD suggest increased platelet degranulation and reduced vWF receptor with regards to healthy controls, specially in CD, but no differences in FBG-related receptors. Inverse moderate correlation between Fcal and Psel in IBD patients suggests depletion of intra-platelet granules at higher levels of gut inflammation.

gastroenterology & hepatology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the description and analysis of platelet activation characteristics in inflammatory bowel disease (IBD), especially whether there are differences in platelet activation markers between IBD patients (including patients with Crohn’s Disease (CD) and Ulcerative Colitis (UC)) compared with healthy controls. The research background points out that platelet markers related to the pro - coagulant state have been described in immune - mediated inflammatory diseases (IMIDs), but the extensive characterization in IBD is still insufficient.

Specifically, the study aims to explore the platelet activation in IBD patients by comparing platelet surface receptors (such as fibrinogen receptor and von Willebrand factor receptor) and platelet activation markers (such as the exposure of P - selectin and CD63) between IBD patients and healthy controls. In addition, the study also investigates whether the changes of these markers are related to the disease activity, for example, by evaluating the fecal calprotectin (Fcal) level.

The research results show that, compared with healthy controls, platelets in IBD patients show a higher degree of degranulation and lower von Willebrand factor receptor expression, especially more significantly in Crohn’s disease patients. Meanwhile, the study finds that there is a moderately strong negative correlation between the Fcal level and the baseline P - selectin level, which may suggest that when the intestinal inflammation level is high, the granules in platelets are depleted. These findings are helpful for understanding the functional changes of platelets in IBD and their potential mechanisms.